A Medicxi-backed start­up looks to tack­le treat­ment-re­sis­tant blood can­cers, and it's go­ing af­ter AML first

In the hard­est-to-treat blood can­cers, re­sis­tance to ther­a­py is an ex­is­ten­tial prob­lem for drug de­vel­op­ers look­ing to per­ma­nent­ly stave off tu­mors. A small biotech is chas­ing an emerg­ing path­way to stop tu­mors’ abil­i­ty to re­sist treat­ment, and its work has caught the eye of a cou­ple of big-name in­vestors.

Kurome Ther­a­peu­tics snared a $15 mil­lion Se­ries A round it will use to iden­ti­fy and de­vel­op a lead pro­gram from its plat­form look­ing at dual in­hibitors of the IRAK1/4 sig­nal­ing path­way and FLT3 pro­tein re­cep­tors on heme blasts to crack treat­ment-re­sis­tant tu­mors, the biotech said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER